MinervaX ApS

MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS), which is responsible for 50% of life-threatening infections in new-born.

Contact name:

Per Fischer


Ole Maaløes Vej 3, 2200 Copenhagen, Denmark

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or 28895854

Copyright 2013 Danskbiotek. All rights reserved.